http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pentacyclic triterpenes from the stem bark of <i>Combretum hartmannianum</i> Schweinf
Morgan, Abubaker M.A.,Mohamed, Azmey E.,Saophea, Chhon,Park, Sang Un,Kim, Young Ho Elsevier 2018 Biochemical systematics and ecology Vol.77 No.-
<P><B>Abstract</B></P> <P>Chemical investigation of the stem bark of <I>Combretum hartmannianum</I> Schweinf (Combretaceae) led to the isolation and identification of nine compounds with pentacyclic triterpene skeletons. These were identified as three ursane-type triterpenes, ursolic acid (<B>1</B>), pomolic acid (<B>2</B>), and corosolic acid (<B>3</B>); one oleanane-type triterpene, arjunic acid (<B>4</B>); and five oleanane-type triterpene glucosides, arjunglucoside I (<B>5</B>), trachelosperoside E-1 (<B>6</B>), combreglucoside (<B>7</B>), chebuloside II (<B>8</B>), and 2α,3β,6β,19α-tetrahydroxyoleanolic acid 28-<I>O</I>-β-<SMALL>D</SMALL>-glucopyranoside (<B>9</B>). The chemical structures of these compounds were elucidated from spectroscopic data and by comparison of these data with previously published results. This is the first report of triterpene compounds from a species of <I>C. hartmannianum</I> and the first report of compounds <B>2</B> and <B>9</B> from a member of the Combretaceae family.</P> <P><B>Highlights</B></P> <P> <UL> <LI> This study is the first comprehensive chemical investigation of <I>Combretum hartmannianum</I> Schweinf. </LI> <LI> Nine compounds were reported first herein as isolates from <I>C. hartmannianum</I>, and compounds 2 and 9 are reported for the first time from Combretaceae family. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Lee, Seohyun,Begley, Charles E.,Morgan, Robert,Chan, Wenyaw,Kim, Sun-Young Mary Ann Liebert, Inc., publishers 2018 Telemedicine and e-Health Vol. No.
<P><B>Abstract</B></P><P><B><I>Background:</I></B><I>As an innovative solution to poor access to care in low- and middle-income countries (LMICs), m-health has gained wide attention in the past decade.</I></P><P><B><I>Introduction:</I></B><I>Despite enthusiasm from the global health community, LMICs have not demonstrated high uptake of m-health promoting policies or public investment.</I></P><P><B><I>Materials and Methods:</I></B><I>To benchmark the current status, this study compared m-health policy readiness scores between sub-Saharan Africa and high-income Organization for Economic Cooperation and Development (OECD) countries using an independent two-sample</I> t <I>test. In addition, the enabling factors associated with m-health policy readiness were investigated using an ordinal logistic regression model. The study was based on the m-health policy readiness scores of 112 countries obtained from the World Health Organization Third Global Survey on e-Health.</I></P><P><B><I>Results:</I></B><I>The mean m-health policy readiness score for sub-Saharan Africa was statistically significantly lower than that for OECD countries (</I>p<I> = 0.02). The enabling factors significantly associated with m-health policy readiness included information and communication technology development index (odds ratio [OR] 1.57; 95% confidence interval [CI] 1.12–2.2), e-health education for health professionals (OR 4.43; 95% CI 1.60–12.27), and the location in sub-Saharan Africa (OR 3.47; 95% CI 1.06–11.34).</I></P><P><B><I>Discussion:</I></B><I>The findings of our study suggest dual policy goals for m-health in sub-Saharan Africa. First, enhance technological and educational support for m-health. Second, pursue global collaboration for building m-health capacity led by sub-Saharan African countries with hands-on experience and knowledge.</I></P><P><B><I>Conclusion:</I></B><I>Globally, countries should take a systematic and collaborative approach in pursuing m-health policy with the focus on technological and educational support.</I></P>
An Unusual Recurrent Bile Leak Following High Grade Liver Trauma
Morgan E Jones,Ee Jun Ban,Charles H. C. Pilgrim 대한외상중환자외과학회 2021 Journal of Acute Care Surgery Vol.11 No.3
Non-operative management of blunt liver injury has been demonstrated as a safe and effective treatment for most grades of injury. As the severity of liver injury increases, so does the risk of complications. A 21-year-old male was brought to the trauma center following a high speed motorbike accident. He underwent a laparotomy and angioembolization for a Grade 4 liver injury. A biloma was diagnosed on Day 18 post injury, and he underwent Endoscopic Retrograde Cholangiopancreatography and biliary stenting which were unsuccessful. There were 2 re-admissions for infected perihepatic collections. In this case, an Endoscopic Retrograde Cholangiopancreatography was not a helpful procedure due to a disconnected liver segment, and morbidity occurred due to instrumentation of the biliary tree (the likely cause of infected biloma). Hepatic resection should be considered for patients who fail non-operative management. Further assessment of efficacy using a larger dataset for analysis is required.
Cardiovascular Fitness and Associated Comorbidities in An Executive Health Program
Otto A Sanchez(Otto A Sanchez ),Anton S. Hesse(Anton S. Hesse ),Morgan R. Betker(Morgan R. Betker ),Christopher J. Lundstrom(Christopher J. Lundstrom ),William E. Conroy(William E. Conroy ),Zan Gao(Za 사피엔시아 2022 Exercise Medicine Vol.6 No.-
Objectives: Low cardiorespiratory fitness, defined as a VO2 max below the 25th percentile for age and sex, is associated with greater body mass index (BMI), blood pressure, and plasma cholesterol values and is an independent risk factor for cardiovascular and metabolic diseases. Given that sedentarism has substantially increased in the U.S. population in the last 20 years and that office workers have the lowest cardiorespiratory fitness of the workforce, we aimed to assess the prevalence of low cardiorespiratory fitness in an corporate wellness program and determine its relationship with associated comorbidities. Methods: For this retrospective observational analysis demographics, height, weight, blood pressure at rest, plasma glucose, lipids, comorbidities, and VO2 max data was extracted from the medical records of 199 participants attending the Executive Health Program at M Health Fairview of the University of Minnesota. Participants were predominantly white, middle-aged men with near-optimal blood pressure values. Results: Participants with low cardiorespiratory fitness had a VO2 max [mean (range) of 28 (19.4 - 36.1) mL/kg/min], and was observed in 33% of all participants. Participants with low cardiorespiratory fitness were more likely to have higher BMI, dyslipidemia and hypertension than those in the excellent to superior category of cardiorespiratory fitness, VO2 max [mean (range) 45.6 (31.8 - 61.2) mL/kg/min]. Prevalence of obesity (17%) was lower than in the general U.S. population, and those who were obese were more likely to be of low cardiorespiratory fitness. Those with low cardiorespiratory fitness had a four fold relative risk of belonging to the group at high risk of cardiovascular and metabolic diseases when compared to those with a fair to superior cardiorespiratory fitness. Conclusions: Low cardiorespiratory fitness identified in a third of all participants, is a modifiable risk factor associated with risk for cardiovascular and metabolic disease, should be evaluated in executive health programs.
The Safety of Flavocoxid, a Medical Food, in the Dietary Management of Knee Osteoarthritis
Sarah L. Morgan,Joseph E. Baggott,Larry Moreland,Renee Desmond,Angela C. Kendrach 한국식품영양과학회 2009 Journal of medicinal food Vol.12 No.5
This study was designed to determine the safety of a medical food, flavocoxid, a proprietary blend of free-B ring flavonoids and flavans from the root of Scutellaria baicalensis (Chinese skullcap) and the bark of Acacia catechu in the dietary management of knee osteoarthritis. The 12-week, randomized, double-blind, placebo-controlled trial in an academic medical center enrolled 59 patients with moderate osteoarthritis of at least one knee who were recruited who were classified as having “below average” to “a moderately above average cardiovascular risk” with a Framingham-based scoring tool. Subjects were randomized to flavocoxid 250mg twice a day versus identical placebo. Safety measures, including recording of adverse events, incidence of serious adverse events, and results of routine laboratory values, were compared between the two groups. There were no major differences in the baseline demographic characteristics of the placebo and flavocoxid groups. With one exception no significant differences were found between the two groups with respect to adverse events by body system, blood pressure, or laboratory values. There was a significantly higher incidence of upper respiratory adverse events in the placebo group (35.4% vs. 5.8%, P=.0003). There were no intra- or inter-group differences in any of the laboratory parameters from study baseline to completion. Thus, flavocoxid is safe when used in a population with “below average” to “moderately above average cardiovascular risk” compared to placebo.